Progressive immune dysfunction with advancing disease stage in renal cell carcinoma
Cancer Cell2021Vol. 39(5), pp. 632–648.e8
Citations Over TimeTop 1% of 2021 papers
David A. Braun, Kelly Street, Kelly P. Burke, David L. Cookmeyer, Thomas Denize, Christina B. Pedersen, Satyen H. Gohil, Nicholas R. Schindler, Lucas Pomerance, Laure Hirsch, Ziad Bakouny, Yue Hou, Juliet Forman, Teddy Huang, Shuqiang Li, Ang Cui, Derin B. Keskin, John A. Steinharter, Gabrielle Bouchard, Maxine Sun, Erica Pimenta, Wenxin Xu, Kathleen M. Mahoney, Bradley A. McGregor, Michelle S. Hirsch, Steven L. Chang, Kenneth J. Livak, David F. McDermott, Sachet A. Shukla, Lars Rønn Olsen, Sabina Signoretti, Arlene H. Sharpe, Rafael A. Irizarry, Toni K. Choueiri, Catherine J. Wu
Related Papers
- → HAVCR/KIM-1 Activates the IL-6/STAT-3 Pathway in Clear Cell Renal Cell Carcinoma and Determines Tumor Progression and Patient Outcome(2014)97 cited
- → Immunometabolism in the tumor microenvironment and its related research progress(2022)28 cited
- → Effect of CHST11, a novel biomarker, on the biological functionalities of clear cell renal cell carcinoma(2024)4 cited
- → SEPT5 overexpression predicts poor prognosis and promotes progression through feedback regulation of HIF-1α in clear cell renal cell carcinoma(2025)2 cited
- → CDCA5 is a potent therapeutic target of clear cell renal cell carcinoma(2022)1 cited